Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1406Neoplasms 1131Prostatic Neoplasms 746Lung Neoplasms 622Colorectal Neoplasms 598Carcinoma, Non-Small-Cell Lung 571Carcinoma, Hepatocellular 416Pancreatic Neoplasms 401Leukemia, Myeloid, Acute 398Stomach Neoplasms 356Multiple Myeloma 327Brain Neoplasms 313Ovarian Neoplasms 309Head and Neck Neoplasms 292Neoplasm Metastasis 277Precursor Cell Lymphoblastic Leukemia-Lymphoma 261Rectal Neoplasms 255Uterine Cervical Neoplasms 248Recurrence 248Melanoma 243Esophageal Neoplasms 237Glioblastoma 232Squamous Cell Carcinoma of Head and Neck 230Lymphoma 214Sarcoma 209Urinary Bladder Neoplasms 194Colonic Neoplasms 192Glioma 191Triple Negative Breast Neoplasms 190Hematologic Neoplasms 183

Interventions

mirdametinib 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × OTHER × Primary Malignant Peripheral Nerve Sheath Tumors × Clear all
NCT06693284 2026-05-29

A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]

University of Minnesota

Phase EARLY_PHASE1 Recruiting
8 enrolled

Primary Malignant Peripheral Nerve Sheath Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡